Kancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer. As a result, Kancera has met...
Read MoreKancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.
Read MoreKancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.
Read Moretwo thirds of patients have now been dosed in the clinical study of KAND567 for the treatment of COVID-19; patient recruitment is expected to be completed during the current quarter, successful scaling up of production of the drug candidate...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) reports preclinical research results, which show that the company's Fractalkine blockers have the potential to disrupt cancer cells' resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) announces that screening of covid-19 patients for the clinical phase II study of KAND567 starts today. The study, which is carried out in collaboration with Capio St. Göran’s Hospital and...
Read MorePreparation for a clinical study with KAND567 in COVID-19 patients now under way Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that independent researchers have published results showing that the fraktalkine system is activated in Covid-19 patients and that...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) announces that an independent research group has published results showing that the company's drug candidate KAND567 has a protective effect on nerve tissue and its function in a preclinical disease model of spinal...
Read MoreThis is a translation of a press release in Swedish dated 2020-05-13 Kancera today announces that the company has submitted an application to the Swedish Medicines Agency for permission to conduct a phase II clinical study of the drug candidate KAND567 in...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) today provides an update on the development of the drug candidate KAND145. Results from the ongoing patenting process underscores the level of innovation of KAND145. In addition, positive clinical results from the Phase...
Read More